Background: Retinopathy of prematurity (ROP), a potentially blinding disease, affects preterm infants. High levels of oxygen saturation are a well-known risk factor for ROP. Objectives: To assess the frequency of ROP type 1 needing treatment after improved oxygen monitoring (2011) in a Mexican preterm population selected for WINROP analyses and to retrospectively revalidate WINROP, an online surveillance system identifying infants at risk of developing ROP type 1. Methods: Preterm infants born with birth weight (BW) <1,750 g and/or at gestational age (GA) ≤34 weeks, screened for ROP in 2012-2014 at the Hospital Civil de Guadalajara, Mexico were included (n = 151). Eighty-five infants with GA <32 weeks qualified for WINROP analyses. GA, BW, maximal ROP stage, ROP treatment and weekly weights were recorded. The results in the present study were compared to those of a previous WINROP study in the same hospital (2005-2010; n = 352). Results: In the present WINROP cohort, 11.8% of the infants born at GA <32 weeks received treatment compared to 51.0% of the infants in the previous WINROP cohort. One infant (3%) born at GA ≥32 weeks received treatment during the present study period compared to 35.6% during the previous period. WINROP displayed 80.0% sensitivity in infants born at GA <32 weeks in the present study compared to 84.7% in the previous study. Conclusions: Uncontrolled oxygen supplementation is the major risk factor for severe ROP in infants born at GA ≥32 weeks. After improved oxygen monitoring, the frequency of ROP treatment was dramatically reduced at the Hospital Civil de Guadalajara, Mexico.

Keywords:
Retinopathy of prematurity, Oxygen, Extremely preterm infants, WINROP algorithm
1.
Gilbert C, Fielder A, Gordillo L, Quinn G, Semiglia R, Visintin P, Zin A: Characteristics of infants with severe retinopathy of prematurity in countries with low, moderate, and high levels of development: implications for screening programs. Pediatrics 2005;115:e518-e525.
2.
Gilbert C: Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control. Early Hum Dev 2008;84:77-82.
3.
Ashton N, Ward B, Serpell G: Effect of oxygen on developing retinal vessels with particular reference to the problem of retrolental fibroplasia. Br J Ophthalmol 1954;38:397-432.
4.
Owen LA, Hartnett ME: Current concepts of oxygen management in retinopathy of prematurity. J Ophthalmic Vis Res 2014;9:94-100.
5.
Gordillo L, Villanueva AM, Quinn GE: A practical method for reducing blindness due to retinopathy of prematurity in a developing country. J Perinat Med 2012;40:577-582.
6.
Urrets-Zavalia JA, Crim N, Knoll EG, Esposito FA, Collino E, Urrets-Zavalia ME, Saenz-de-Tejada G, Torrealday JI, Serra HM, Gilbert C: Impact of changing oxygenation policies on retinopathy of prematurity in a neonatal unit in Argentina. Br J Ophthalmol 2012;96:1456-1461.
7.
Löfqvist C, Andersson E, Sigurdsson J, Engstrom E, Hård AL, Niklasson A, Smith LEH, Hellström A: Longitudinal postnatal weight and insulin-like growth factor i measurements in the prediction of retinopathy of prematurity. Arch Ophthalmol 2006;124:1711-1718.
8.
Binenbaum G, Ying GS, Quinn GE, Huang J, Dreiseitl S, Antigua J, Foroughi N, Abbasi S: The chop postnatal weight gain, birth weight, and gestational age retinopathy of prematurity risk model. Arch Ophthalmol 2012;130:1560-1565.
9.
Hellström A, Hård AL, Engstrom E, Niklasson A, Andersson E, Smith L, Löfqvist C: Early weight gain predicts retinopathy in preterm infants: new, simple, efficient approach to screening. Pediatrics 2009;123:E638-E645.
10.
Wallace DK, Kylstra JA, Phillips SJ, Hall JG: Poor postnatal weight gain: a risk factor for severe retinopathy of prematurity. J AAPOS 2000;4:343-347.
11.
Early Treatment for Retinopathy of Prematurity Cooperative Group: Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 2003;121:1684-1694.
12.
Löfqvist C, Hansen-Pupp I, Andersson E, Holm K, Smith LEH, Ley D, Hellström A: Validation of a new retinopathy of prematurity screening method monitoring longitudinal postnatal weight and insulin-like growth factor I. Arch Ophthalmol 2009;127:622-627.
13.
Choi JH, Löfqvist C, Hellström A, Heo H: Efficacy of the screening algorithm WINROP in a Korean population of preterm infants. JAMA Ophthalmol 2013;131:62-66.
14.
Hård AL, Löfqvist C, Fortes JB, Procianoy RS, Smith L, Hellström A: Predicting proliferative retinopathy in a Brazilian population of preterm infants with the screening algorithm WINROP. Arch Ophthalmol 2010;128:1432-1436.
15.
Wu C, Löfqvist C, Smith LEH, VanderVeen DK, Hellström A, Consortium W: Importance of early postnatal weight gain for normal retinal angiogenesis in very preterm infants: a multicenter study analyzing weight velocity deviations for the prediction of retinopathy of prematurity. Arch Ophthalmol 2012;130:992-999.
16.
Zepeda-Romero LC, Hård AL, Gomez-Ruiz LM, Gutierrez-Padilla JA, Angulo-Castellanos E, Barrera-de-Leon J, Ramirez-Valdivia JM, Gonzalez-Bernal C, Valtierra-Santiago CI, Garnica-Garcia E, Löfqvist C, Hellström A: Prediction of retinopathy of prematurity using the screening algorithm WINROP in a Mexican population of preterm infants. Arch Ophthalmol 2012;130:720-723.
17.
Piyasena C, Dhaliwal C, Russell H, Hellström A, Löfqvist C, Stenson BJ, Fleck BW: Prediction of severe retinopathy of prematurity using the WINROP algorithm in a birth cohort in South East Scotland. Arch Dis Child Fetal Neonatal Ed 2014;99:F29-F33.
18.
Kramer MS, Platt RW, Wen SW, Joseph KS, Allen A, Abrahamowicz M, Blondel B, Breart G: A new and improved population-based Canadian reference for birth weight for gestational age. Pediatrics 2001;108:E35.
19.
International Committee for the Classification of Retinopathy of Prematurity: The international classification of retinopathy of prematurity revisited. Arch Ophthalmol 2005;123:991-999.
20.
Stoltz Sjostrom E, Lundgren P, Ohlund I, Holmstrom G, Hellström A, Domellof M: Low energy intake during the first 4 weeks of life increases the risk for severe retinopathy of prematurity in extremely preterm infants. Arch Dis Child Fetal Neonatal Ed 2016;101:F108-113.
21.
Tolsma KW, Allred EN, Chen ML, Duker J, Leviton A, Dammann O: Neonatal bacteremia and retinopathy of prematurity: The ELGAN study. Arch Ophthalmol 2011;129:1555-1563.
22.
Lundgren P, Kistner A, Andersson EM, Hansen Pupp I, Holmstrom G, Ley D, Niklasson A, Smith LE, Wu C, Hellström A, Löfqvist C: Low birth weight is a risk factor for severe retinopathy of prematurity depending on gestational age. PLoS One 2014;9:e109460.
23.
Ehrenkranz RA: Steroids, chronic lung disease, and retinopathy of prematurity. Pediatrics 1992;90:646-647.
24.
Brown DR, Biglan AW, Stretavsky MM: Retinopathy of prematurity: The relationship with intraventricular hemorrhage and bronchopulmonary dysplasia. J Pediatr Ophthalmol Strabismus 1990;27:268-271.
25.
Arroe M, Peitersen B: Retinopathy of prematurity: review of a seven-year period in a Danish neonatal intensive care unit. Acta Paediatr 1994;83:501-505.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.